Through GLP-1 and GIP receptor agonism, retatrutide augments glucose-dependent insulin secretion and improves the function of the pancreatic beta cell, while GLP-1 signaling also suppresses inappropriate glucagon secretion in the fed state
For weight management purposes, the dosing schedule is more aggressive, starting at 0.25 mg weekly for four weeks, then escalating to 0.5 mg for four weeks, followed by 1.0 mg for four weeks, 1.7 mg for four weeks, and finally reaching the maintenance dose of 2.4 mg weekly
Switching within drug classes Switching from one GLP-1 to another , such as moving from semaglutide to tirzepatide, is a different kind of transition entirely
The mean (SD) reduction of body weight from baseline was 4.74 (1.687) kg on day 29 in 15mg dose cohort compared to 0.45 (1.460) kg in the placebo cohort
The bioavailability of these compounds can be significantly influenced by how and when they are taken